United Therapeutics Corp (UTHR)
235.52
-0.43
(-0.18%)
USD |
NASDAQ |
Apr 26, 13:44
United Therapeutics Revenue (TTM): 2.328B for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 2.328B |
September 30, 2023 | 2.204B |
June 30, 2023 | 2.111B |
March 31, 2023 | 1.981B |
December 31, 2022 | 1.936B |
September 30, 2022 | 1.86B |
June 30, 2022 | 1.789B |
March 31, 2022 | 1.768B |
December 31, 2021 | 1.686B |
September 30, 2021 | 1.655B |
June 30, 2021 | 1.591B |
March 31, 2021 | 1.506B |
December 31, 2020 | 1.483B |
September 30, 2020 | 1.410B |
June 30, 2020 | 1.431B |
March 31, 2020 | 1.442B |
December 31, 2019 | 1.449B |
September 30, 2019 | 1.519B |
June 30, 2019 | 1.530B |
March 31, 2019 | 1.601B |
December 31, 2018 | 1.628B |
September 30, 2018 | 1.711B |
June 30, 2018 | 1.744B |
March 31, 2018 | 1.744B |
December 31, 2017 | 1.725B |
Date | Value |
---|---|
September 30, 2017 | 1.670B |
June 30, 2017 | 1.632B |
March 31, 2017 | 1.600B |
December 31, 2016 | 1.599B |
September 30, 2016 | 1.595B |
June 30, 2016 | 1.573B |
March 31, 2016 | 1.507B |
December 31, 2015 | 1.466B |
September 30, 2015 | 1.407B |
June 30, 2015 | 1.351B |
March 31, 2015 | 1.327B |
December 31, 2014 | 1.288B |
September 30, 2014 | 1.231B |
June 30, 2014 | 1.203B |
March 31, 2014 | 1.161B |
December 31, 2013 | 1.117B |
September 30, 2013 | 1.072B |
June 30, 2013 | 1.012B |
March 31, 2013 | 957.00M |
December 31, 2012 | 916.08M |
September 30, 2012 | 867.44M |
June 30, 2012 | 826.71M |
March 31, 2012 | 784.88M |
December 31, 2011 | 743.18M |
September 30, 2011 | 711.70M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
1.410B
Minimum
Sep 2020
2.328B
Maximum
Dec 2023
1.720B
Average
1.655B
Median
Sep 2021
Revenue (TTM) Benchmarks
Liquidia Corp | 17.49M |
Esperion Therapeutics Inc | 116.33M |
Vertex Pharmaceuticals Inc | 9.869B |
Heron Therapeutics Inc | 127.04M |
Aldeyra Therapeutics Inc | -- |